Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

NCT02384317 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen